Medical Informatics and Rare Disease: a bridge between two worlds
IQVIA, medical informatics, rare disease, rare disease research
0 Comment
Debates
ICSs – an opportunity to improve Patient & Market Access at a local level
integrated care systems, IQVIA, market access, NHS, NHS legislation, UK market access
0 Comment
Innovative contracting in Europe – a Trojan horse?
health systems, innovative contracting, patient access, ZS Associates
0 Comment
Launch excellence in a disrupted world – challenges & opportunities
best practice in launch, future of launch excellence, IQVIA, launch approaches, launch excellence
0 Comment
11/06/2017
Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard
cancer, market access, NHS, pharma, QuinitilesIMS, Vanguard
0 Comment
A unique example of partnership working across the health system, focusses on the service at large, not just the pill, and uses leading-edge data analytics to analyse, benchmark and visualise the current state of the cancer pathways within the Cancer Vanguard Trusts. Furthermore, it encompasses multiple aspects of the service provision ranging from patient outcomes and experiences, the flow of treatment and the usage of medicine in order to inform an evidence-based and patient-centric approach to service redesign and resource optimisation.
06/09/2017
Pharma and proactive, preventative healthcare: how to use the pharmacy channel
Across Europe, a shift towards greater prevention, earlier diagnosis and treatment is needed in order to contain the growing cost of healthcare. This webinar hosted by pharmaphorum with sponsor PHOENIX group looks at how harnessing the data and expertise of pharmacies, and via greater engagement with patients, consumers and shoppers can meet this emerging need.
20/06/2017
Disruption and maturity: the future directions for biologics
biologics, biosimilars, Brexit, NHS
0 Comment
Is the UK’s NHS saving enough from the new wave of biosimilars?
When small becomes big: orphan medicines, advances, access and affordability
Significant unmet need still remains in the rare disease market, only around 5% of rare diseases currently have an approved drug treatment. This represents a major opportunity for the pharmaceutical industry. Our webinar will assess the critical factors underpinning success in the rare disease space and provide a view into the future of market access and health technology assessments for orphan medicines – alongside the impact on R&D and clinical trials – in the context of Brexit negotiations.